Fennec Pharmaceuticals Incis A Biopharmaceutical Company Based In Durhamnorth Carolinafocused On Developing Oncology Therapeuticsparticularly For Pediatric Cancer Carethe Company Is Publicly Traded On Nasdaq And The Toronto Stock Exchangefennec Is Dedicated To Addressing Unmet Medical Needs In Pediatric Oncologyemphasizing Innovation In Drug Development To Enhance Patient Outcomes One Of Its Key Products Is Pedmarkapedmarqsia A Sodium Thiosulfate Injection Designed To Reduce Cisplatin Induced Ototoxicity In Pediatric Patients With Localizednon Metastatic Solid Tumorsfennec Has Recently Expanded Its Market Presence By Launching Pedmarqsiain Germanycomplementing Its Established Operations In The U Sthe Company Engages Healthcare Providers Through Regional Pediatric Oncology Specialists And Medical Science Liaisonstargeting Pediatric Patients Undergoing Platinum Based Chemotherapy Fennec S Mission Is To Improve The Quality Of Life For Patients And Fill Gaps In Pediatric Oncology Careaiming To Become A Leader In Chemoprotectant Therapies For Chemotherapy Induced Toxicities
